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Abstract: Mycophenolate mofetil (MMF), a prodrug of mycophenolic acid (MPA), is an 
inhibitor of inosine monophosphate dehydrogenase (IMPDH). It preferentially inhibits denovo 
pathway of guanosine nucleotide synthesis in T and B-lymphocytes and prevents their prolif-
eration, thereby suppresses both cell mediated and humoral immune responses. Clinical trials 
in kidney transplant recipients have shown the efﬁ  cacy of MMF in reducing the incidence and 
severity of acute rejection episodes. It also improves long term graft function as well as graft and 
patient survival in kidney transplant recipients. MMF is useful as a component of toxicity sparing 
regimens to reduce or avoid exposure of steroids or calcineurin inhibitor (CNI). Enteric-coated 
mycophenolate sodium (EC-MPS) can be used as an alternative immunosuppressive agent in 
kidney transplant recipients with efﬁ  cacy and safety proﬁ  le similar to MMF.
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Introduction
Ongoing attempts to develop new immunosuppressive agents to achieve adequate 
immunosuppression with minimal toxicity have lead to discovery of several newer 
agents with different mechanism of actions. The introduction of mycophenolate mofetil 
in the mid-1990s has altered the management of immunosuppression in solid organ 
transplantation.
Mycophenolate mofetil (MMF) is an ester prodrug of mycophenolic acid (Figure 1). 
Mycophenolic acid (MPA)is a fermentation product of Penicillium brevicompactum 
and related fungi.1 It was discovered by Gosio in 1893 and was shown to have weak 
antibacterial activity.2 Its ability to inhibit inosine-5’-monophosphate dehydrogenase 
(IMPDH) was ﬁ  rst identiﬁ  ed in 1969.3 Initial studies with MMF in animal models of 
organ transplantation yielded encouraging results and led to the initiation of human 
trials.4,5 Sollinger et al conducted the ﬁ  rst human trial of MMF in 1992 in kidney 
transplant recipients.6 Since then, MMF has been used in combination with other 
medications to prevent acute rejections, for rescue treatment in acute rejection episodes 
and as adjuvant to facilitate “sparing” of other immunosuppressive agents.
Mechanism of action
Two major pathways are involved in purine synthesis: the de novo pathway and the 
salvage pathway. MPA inhibits IMPDH, the rate-limiting enzyme in the de novo path-
way of purine synthesis (Figure 2). By inhibiting IMPDH, MPA prevents formation of 
guanosine monophosphate (GMP). Cells depleted of GMP cannot synthesize guanine 
triphosphate (GTP) and deoxy guanine triphosphate (d-GTP), and therefore cannot 
replicate. Most mammalian cells are able to maintain GMP levels via the purine salvage 
pathway. MPA is 5-fold more potent as an inhibitor of the type II isoform of IMPDH, Therapeutics and Clinical Risk Management 2009:5 140
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which is expressed in activated T and B lymphocytes, than of 
the type I isoform, which is expressed in most cell types.7 Due 
to the expression of the more susceptible form of IMPDH, 
MPA preferentially inhibits the de novo guanosine nucleo-
tide synthesis in lymphocytes. Monocytes are also affected 
by therapeutic doses of MPA, as it signiﬁ  cantly decreases 
guanosine triphosphate (GTP) pools in human peripheral 
blood monocytes but not in neutrophils.8 By preferential 
depletion of guanosine and deoxyguanosine nucleotides in 
T and B lymphocytes, MPA suppresses both cell mediated 
immune responses and antibody formation, major factors in 
both acute and chronic allograft rejection.
In addition to inhibition of DNA synthesis in lympho-
cytes, depletion of guanosine nucleotides suppresses the 
expression of several adhesion receptors including vascu-
lar cell adhesion molecule 1 (VCAM-1), E-selectin, and 
P-selectin on vascular endothelial cells.9 This interferes 
with the attachment of leukocytes to endothelial cells and 
prevents the recruitment of lymphocytes and monocytes to 
sites of inﬂ  ammation.10,11 Suppression of mononuclear cell 
recruitment is another mechanism by which MMF decreases 
acute and chronic graft rejection.
MMF causes depletion of GTP and thereby depletion 
of tetrahydrobiopterin – a cofactor that limits the rate of 
inducible nitric oxide synthases (iNOS) activity, but not that 
of endothelial nitric oxide synthases (eNOS). Activation of 
iNOS is correlated with renal allograft rejection. Suppression 
of iNOS activity and NO production is presumably one of the 
mechanisms by which MMF prevents allograft rejection.12
Pharmacokinetics
Pharmacokinetics of MMF has been investigated in healthy 
volunteers and in renal allograft recipients. MPA is poorly 
absorbed, so the 2-morpholinoethyl ester, mycophenolate 
mofetil was developed to allow oral dosing. Following oral 
administration, MMF absorbs rapidly and completely and 
undergoes hepatic de-esteriﬁ  cation to form MPA – an active 
immunosuppressant. Bioavaibility of MPA from MMF is 
about 94% and reaches peak plasma concentration about 
2 hours after oral administration.13 MPA undergoes hepatic 
glucuronidation to form mycophenolic acid glucuronide 
(MPAG), which is pharmacologically inactive. MPAG is 
secreted into the bile and it is converted back to MPA by gut 
bacteria. MPA is then reabsorbed and via hepatic recircula-
tion produces second peak between 8 and 12 hours.13 MMF 
gets excreted in the urine as MPAG, accounting for 90% of 
the administered MMF dose.14 In renal transplant recipients 
during acute renal impairment in the early post-transplant 
period, the plasma MPA concentrations are comparable to 
patients without renal failure, whereas plasma MPAG con-
centrations are 2- to 3-fold higher. Renal failure or hemodi-
alysis has no effect on plasma concentration of free MPA and 
no dosage adjustment is required for such patients.15
Concomitant administration of other immunosup-
pressive agents can inﬂ  uence pharmacokinetics of MPA. 
Cyclosporine (CSA) inhibits the biliary excretion of MPAG, 
thereby reduces the enterohepatic recirculation of MPAG. 
Tacrolimus (TAC) and sirolimus (SRL) do not interfere with 
biliary excretion of MPAG. So, the second MPA peak due 
to enterohepatic circulation is more pronounced in patients 
receiving TAC or SRL compared to CSA. However, higher 
MPAG concentration displaces MPA from binding sites 
and increases free MPA concentration, possibly similar 
to that seen with TAC or SRL based therapy.16–18 In the 
clinical setting, the level of MPA exposure correlates with 
the risk of developing acute rejection. MPA area under the 
curve (AUC) 30 mg.h/L was associated with signiﬁ  cant 
increased risk of acute allograft rejection and there was 
no additional reduction in the allograft rejection found for 
MPA AUC  60 mg.h/L in kidney transplant recipients on 
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Figure 1 Chemical structure of mycophenolate mofetil (MMF) – the morpholinoethyl ester of mycophenolic acid (MPA) – mycophenolate.Therapeutics and Clinical Risk Management 2009:5 141
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conventional doses of CSA.19,20 The proposed therapeutic 
window of the MPA AUC0–12 is 30 to 60 mg.h/L. Currently, 
MPA therapeutic level monitoring is recommended only dur-
ing early post-transplantation period for the patients at higher 
risk of developing acute allograft rejection.21 Usefulness of 
abbreviated 2-hour MPA AUC measurement to predict MPA 
AUC12 hour has been suggested by some studies.22,23 However, 
this abbreviated sampling strategy require strict adherence 
to the blood sample collection time and it can miss MPA 
enterohepatic recirculation, which is especially important in 
patients on simultaneous TAC or SRL therapy.15
Prevention of acute renal 
allograft rejection
Acute allograft rejection usually occurs within the ﬁ  rst 
3 to 6 months post transplantation, being one of the most 
signiﬁ  cant problems in transplant recipients. Acute rejection 
is not only the principal cause of early graft loss, but it also 
increases the risk of late graft loss by predisposing to irre-
versible chronic rejection. MMF has been shown to prevent 
acute graft rejection following renal transplantation in animal 
experiments.4,5
The evidence of safety and efﬁ  cacy of MMF in the pre-
vention of acute renal allograft rejection from three large, 
randomized, multicenter, human clinical trials was instrumen-
tal in MMF being approved by the US Food and Drug Admin-
istration (FDA) and European agencies. All three studies 
(Table 1) had similar design, using MMF 2 g/day (1000 mg 
bid) or 3 g/day (1500 mg bid) plus CSA and corticosteroids 
as an immunosuppressive regimen, with or without induction 
therapy.24–26 The US and Tricontinental study groups compared 
MMF with azathioprine (AZA), while the European study 
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Figure 2 Mechanism of action – Inhibition of de novo pathway of purine synthesis by mycophenolate mofetil.
Abbreviations: HGPRT, hypoxanthine-guanine phosphoribosyl; IMPDH, inosine monophosphate dehydrogenase.Therapeutics and Clinical Risk Management 2009:5 142
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group compared MMF with placebo. The primary efﬁ  cacy 
endpoint was biopsy-proven acute rejection (BPAR) or treat-
ment failure (deﬁ  ned as allograft loss, patient withdrawal or 
death) during the ﬁ  rst 6 months after transplantation.
US Renal Transplant Mycophenolate Mofetil Study 
Group randomized 499 patients to either MMF (2 g/d or 
3 g/d) or AZA 1 to 2 mg/kg/d. Cyclosporine, corticosteroids 
and antithymocyte globulin were administered as part of a 
quadruple sequential induction protocol. The incidence of 
ﬁ  rst BPAR or treatment failure was signiﬁ  cantly reduced in 
the MMF 2 g/d group (31.1%, p = 0.0015) and in the MMF 
3 g/d group (31.3%, p = 0.0021), compared to 47.6% in 
the AZA group. First episode of BPAR alone occurred in 
38% of patients who received AZA compared with 19.8% 
and 17.5% of patients who received MMF 2 g/d and 3 g/d, 
respectively. Time to ﬁ  rst BPAR episode or treatment failure 
was signiﬁ  cantly longer for MMF 2 g/d vs AZA (p = 0.0036) 
and MMF 3 g/d vs AZA (p = 0.0006).26
In the European Mycophenolate Mofetil Cooperative 
Study Group, 491 patients were randomized to either placebo, 
MMF 2 g/d or MMF 3 g/d. Patients received CSA and 
corticosteroids as part of maintenance immunosuppression. 
However, no induction therapy was given. At 6 months, the 
incidence of BPAR or treatment failure was 56.0%, 30.3% 
and 38.8% in placebo, MMF 2 g/d and MMF 3 g/d groups 
respectively (p  0.001 for both MMF groups, compared to 
placebo). The corresponding percentages for BPAR were 
46.4%, 17.0% and 13.8% respectively.24
The Tricontinental Mycophenolate Mofetil Renal Trans-
plantation Study Group compared the efﬁ  cacy and safety 
of MMF with AZA, in patients receiving a ﬁ  rst or second 
cadaveric renal graft in a prospective double blind, random-
ized trial. No induction therapy was given. BPAR or treat-
ment failure occurred in 50% of patients in the AZA group 
by 6 months after transplantation, compared with 38.2% in 
the MMF 2 g/d group (p = 0.0287) and 34.8% in the MMF 
3 g/d group (p = 0.0045). The incidence of BPAR was 19.7% 
in the MMF 2 g/d group, 15.9% in the MMF 3 g/d group 
and 35.5% in the AZA group. At the end of 1 year after 
transplantation, the graft survival in the MMF groups was 
superior to that in the AZA group, although this difference 
was not statistically signiﬁ  cant.25
Efﬁ  cacy data analysis from the three trials mentioned 
above, comprising 1493 patients, showed superiority 
of MMF 2 g/d and MMF 3 g/d over AZA or placebo 
in preventing biopsy proven acute allograft rejection at 
12 months post transplantation. The rejection episodes 
were less severe in the MMF group. Also, the need for 
anti lymphocyte globulin and the number of full courses of 
steroids required to treat rejection episodes were reduced 
by more than 60% in MMF group. There was an absolute 
reduction in the incidence of graft loss due to acute rejection 
in the MMF group compared to the AZA or the placebo 
group. Although, MMF treatment reduced the incidence 
and severity of acute rejection episodes, there was no sig-
niﬁ  cant difference in patient survival and graft survival at 
the end of 1 year.27
All three trials were done using the old formulation of 
CSA. Remuzzi et al (MYSS trial) used the micro-emulsion 
preparation of CSA (Neoral) in patients receiving their ﬁ  rst 
kidney transplant from cadaveric donors.28 During phase A, 
all patients received either MMF 2 g/d or AZA (100 mg/d 
if bodyweight 75 kg, 150 mg/d if 75 kg) and steroids 
for immunosuppression for 6 months. At the end of 6 
months, patients with less than 2 episodes of acute rejec-
tion, no episodes of steroid resistant rejection, stable serum 
creatinine level and urinary protein excretion less than 1 
g/d entered phase B. During phase B, steroids were gradu-
ally tapered and discontinued over 90 days in both groups. 
At the end of 6 months (phase A) and 21 months (phase 
B), the incidence of BPAR was similar in the MMF and 
AZA groups. Graft losses due to refractory rejections and 
adverse events were also comparable in both groups. Cost 
of MMF therapy was 15 times higher than AZA therapy. 
In this study, investigators monitored and tried to maintain 
trough CSA levels between 150 and 250 μg/L, which was 
achieved in most patients. This could probably explain low 
rejection rates in both groups.28
Table 1 Summary table of MMF pivotal trials
Trial MMF group Control group Induction BPAR at 6 months
US Renal Transplantation Study26 MMF/CSA/CS AZA/CSA/CS ATG MMF better
European Study24 MMF/CSA/CS Placebo/CSA/CS No MMF better
Tricontinental Study25 MMF/CSA/CS AZA/CSA/CS No MMF better
MYSS Study28 MMF/Neoral/CS AZA/Neoral/CS No No difference
Abbreviations: MMF, mycophenolate mofetil; AZA, azathioprine; CS, corticosteroids; CSA, cyclosporine; ATG, antithymocyte globulin; Neoral, microemusion cyclosporine; 
BPAR, biopsy proven acute rejection.Therapeutics and Clinical Risk Management 2009:5 143
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At the end of 72 months of follow up of patients in the 
MYSS trial, investigators found that the incidences of graft 
loss (6.8% vs 6.1%, p = 0.82), late rejections (6 mo after 
transplantation, 25.3% vs 21.2%; p = 0.53), mean glomerular 
ﬁ  ltration rate (GFR) and adverse events were similar in the 
AZA (n = 124) and the MMF (n = 124) groups, respectively. 
Since both drugs, AZA and MMF have similar risk/beneﬁ  t 
proﬁ  les, authors of this study recommended routine use 
of AZA over MMF in combination with micro-emulsion 
preparation of CSA to save on the cost of immunosuppres-
sive therapy.29
Long term allograft survival
In the above studies, MMF was comparable to or better 
than AZA in reducing the episodes of acute allograft rejec-
tions at 1 year post transplantation. The Tricontinental 
study group reported the impact of long-term MMF use 
on allograft survival. At the end of 3 years, analysis of the 
Tricontinental study showed similar graft survival with 
AZA and both strengths of MMF, but graft loss due to acute 
rejection was reduced in the MMF 2 g/d and 3 g/d groups 
(5.8% and 3%, respectively), compared to 9.9% in the AZA 
group. Of patients who experienced a BPAR episode within 
6 months of transplantation, 31.5% lost their graft by the end 
of 3 years. In contrast, only 6.6% of patients who had no early 
acute rejection lost their graft by the end of the 3-year study 
period. Adding MMF to the standard immunosuppressive 
therapy and thereby reducing the incidence of acute rejec-
tion may also result in an improvement in long-term graft 
and patient survival.30
Retrospective analysis of data collected between 1988 and 
1997 of 66,774 renal transplant recipients in the US registry, 
conﬁ  rmed protective effect of MMF on long term allograft 
survival. Acute rejection was the strongest risk factor for 
late graft loss with risk ratio of 2.41 (p  0.001). MMF 
therapy was associated with a decrease in the incidence of 
acute rejection, compared to AZA. In a multivariate analysis, 
after controlling for acute rejection, MMF therapy reduced 
the relative risk for development of chronic allograft failure 
(CAF) by 27% (risk ratio [RR] 0.73, p  0.001) compared 
to AZA therapy. This analysis conﬁ  rmed that MMF therapy 
was an independent protective factor in preventing CAF, 
not related to the decrease in acute allograft rejection. The 
authors suggested that the independent protective effect of 
MMF was possibly related to prevention of chronic allograft 
arteriopathy by decreasing vascular intimal hyperplasia.31
Analysis of data from the US renal system of 49,666 
primary renal transplant recipients evaluated the effect of 
long-term continuous MMF or AZA use on renal allograft 
function. The results showed that the continuous use of MMF 
had a protective effect against declining renal function, as 
measured by the slope of reciprocal creatinine, compared to 
continuous AZA use (p  0.001).32 MMF was associated 
with a 65% reduced risk of late acute rejection compared with 
AZA (p  0.001). The incidence of acute rejection episodes 
at 2 and 3 years post transplantation was signiﬁ  cantly lower 
in the MMF group (0.9% at 2 years, 1.1% at 3 years) than in 
the AZA group (6.1% at 2 years, 9.3% at 3 years).33
Rescue therapy for acute renal 
allograft rejection
Trials have looked at the efﬁ  cacy of MMF as treatment for 
acute refractory rejection episodes, both as an alternative and 
as an adjunct to high-dose corticosteroids. The MMF Renal 
Refractory Rejection Study Group, in an open label ran-
domized multicenter trial, compared the efﬁ  cacy and safety 
of MMF with high dose intravenous (IV) steroids for the 
treatment of refractory, acute cellular rejection in recipients 
of ﬁ  rst or second cadaveric or living-donor renal allografts. 
A total of 150 patients were randomized to receive either 
high-dose IV steroids for 5 days followed by a 5-day taper 
to 20 mg/d (n = 77) or oral MMF 1.5 g twice daily (n = 73). 
Patients treated with high dose steroids were maintained on 
AZA. All patients received maintenance CSA and steroid 
therapy. MMF reduced graft loss and death by 45% compared 
to IV steroid group at the end of 6 months. The number of 
patients requiring full courses of IV steroids for subsequent 
rejection episodes were similar in both groups but patients 
who received full courses of anti lymphocyte globulin were 
more than double in IV steroid group (n = 18) compared to 
the MMF group (n = 8).34
A two-phase trial evaluated MMF as an adjunctive ther-
apy in 221 patients with acute rejection episodes. In phase 1, 
patients with acute rejection between 7 days and 6 months 
post transplantation were randomized to receive IV steroids 
combined with either MMF (1.5 g twice daily) or AZA. At the 
end of 1 year, incidence of recurrent or persistent rejection or 
treatment failure was signiﬁ  cantly lower in the MMF group 
compared to the AZA group (29.2% vs 51.9%, respectively; 
p = 0.0006). Patients in the AZA group were also more likely 
to require at least one course of antithymocyte globulin.35
In summary, MMF was found to be more effective as a 
rescue therapy in acute renal allograft rejection treatment 
as compared to AZA or high dose IV steroid treatment. 
Treatment with MMF also reduced the episodes of subse-
quent rejections and graft loss due to acute rejection.Therapeutics and Clinical Risk Management 2009:5 144
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Toxicity-sparing protocols
Use of triple drug maintenance regimens including – a 
calcineurin inhibitor, steroids and MMF, have reduced the 
incidence of acute rejection in renal transplant recipients.36 
However, the long-term use of steroids and CNIs is associated 
with numerous potentially toxic effects that can impact over-
all graft or patient survival. Recent studies have evaluated 
MMF as part of different immunosuppressive maintenance 
regimens to facilitate withdrawal or avoidance of steroids 
and CNIs in renal transplant recipients.
Calcineurin inhibitors-sparing regimens
CNIs have been useful in reducing the incidence acute 
allograft rejections during the early post-transplantation 
period.37,38 Nephrotoxicities like renal vasoconstriction, 
reduced glomerular ﬁ  ltration rate, arterial hypertension and 
interstitial ﬁ  brosis, can develop in both native and trans-
planted kidneys with prolonged use of CNIs. Other adverse 
effects of CNIs use include hyperlipidemia, neurotoxicity 
and impaired glucose metabolism.39–41 These can ultimately 
lead to chronic allograft dysfunction and poor patient and/or 
graft survival. Since MMF has emerged as highly effective 
immunosuppressive agent with no known nephrotoxicity, 
attempts have been made to develop protocols to minimize 
CNIs exposure by dosage reduction, withdrawal or complete 
avoidance, to improve long term allograft survival.
Initially, studies were done to withdraw CSA in renal 
transplant recipients with stable renal function at 12 months 
post transplantation. In a prospective study, 64 stable renal 
transplant recipients on CSA and prednisone were random-
ized for conversion of CSA to 2 mg/kg/d AZA (n = 30) or 
1 g of MMF twice daily (n = 34). All patients remained on 
low dose steroids. At the end of four months after conversion, 
the incidence of acute rejection was lower in the MMF group 
(4/34) compared to the AZA group (11/30) (p = 0.04).42 In 
two other studies, the incidence of acute rejection using MMF 
and steroids to withdraw CSA at 12 months after transplanta-
tion was similar to the above study (10.6% and 11.8%).43,44 
A signiﬁ  cant number of patients in the CSA withdrawal group 
had improved renal function in all three studies.42–44
While the above studies established safety and efﬁ  cacy 
of MMF in CNI withdrawal in patients with stable renal 
function, in the “Creeping Creatinine Study”, Dudley et al 
attempted to withdraw CSA in patients with deteriorating 
renal function at least 6 months post transplantation. These 
patients were randomized to either continue CSA or to add 
MMF with gradual withdrawal of CSA over a 6-week period. 
At 6 month follow up, patients in CSA withdrawal/MMF 
group had stabilization or improvement in renal function 
without increase in acute allograft rejection.45
Complete avoidance of CNIs was attempted using MMF 
based immunosuppression in some trials recently. In most of 
the studies, some form of induction therapy was used to avoid 
early post-transplantation rejection.46–54 In a randomized study 
comparing MMF/SRL/steroids to MMF/TAC/steroids, Larson 
et al did not ﬁ  nd any difference in renal function at 12 months 
post transplantation. The incidence of acute rejection was 
10% in the TAC group and 13% in the SRL group (p = 0.58). 
Patient survival and graft survival were also comparable in 
both groups.55 Flechner et al published 5-year outcome data 
from a randomized prospective trial in primary adult renal 
allograft recipients, comparing MMF/SRL/steroids (n = 31) 
to MMF/CSA/steroids (n = 30). At 5 years both groups had 
comparable acute rejection rates (12.9% vs 23.3%, p = 0.22) 
and patient survival (87.1% vs 90%, p = 0.681). Although 
unadjusted patient survival was similar, SRL/MMF based 
CNI-free patients had longer death censored graft survival 
(96.4% vs 76.7%, p = 0.0265), higher glomerular ﬁ  ltration 
rate (66.7 vs 50.7 cc/min, p = 0.0075), and fewer graft losses 
from chronic allograft nephropathy.56
Investigators evaluated efficacy and safety of four 
different MMF based immunosuppressive regimens in 
the Elite-Symphony study. They randomized 1645 renal 
transplant recipients to receive standard-dose CSA, MMF 
and corticosteroids, or daclizumab induction, MMF and 
corticosteroids in combination with low-dose CSA, or low-
dose TAC, or low-dose SRL. At the end of 12 months post 
transplantation, the rate of BPAR was signiﬁ  cantly lower in 
MMF/TAC group compared to the other three groups. The 
mean calculated GFR and overall graft survival were also 
better in the MMF/TAC group.57
Srinivas et al analyzed the data of solitary kidney trans-
plant recipients reported to the Scientiﬁ  c Registry of Renal 
Transplant Recipients (2000–2005) to compare outcomes 
of different immunosuppressive regimens. MMF/SRL 
combination was associated with higher risk of acute rejec-
tion at the end of 6 months post transplantation compared 
to MMF/TAC (p  0.01). Kaplan-Meier analysis showed 
inferior overall graft and patient survival with MMF/SRL 
compared to MMF/TAC and MMF/CSA at the end of 3 years 
post transplantation.58
Steroid-sparing regimens
Steroid therapy in transplant recipients is associated with the 
development of several side effects like hypertension, weight 
gain, poor glucose tolerance, dyslipidemia, osteoporosis Therapeutics and Clinical Risk Management 2009:5 145
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and hip fracture, avascular necrosis of joints and sepsis.59 
However, withdrawal of steroids can precipitate acute rejec-
tion episodes in renal transplant recipients. Before the era 
of MMF, trials with late steroid withdrawal (3 months 
post transplantation) were associated with a signiﬁ  cant 
increase in acute allograft rejection and late graft loss.60,61 
In a prospective randomized steroid withdrawal trial using 
AZA and CSA as maintenance therapy, 2-year graft survival 
was 78% in early steroid withdrawal group (at 2 weeks) vs 
86% in later steroid withdrawal group (6 months post 
transplantation). Withdrawal of steroids was successful in 
only 13 of 42 patients (41%) in the early withdrawal group 
and 59 of 75 patients (79%) in the late withdrawal group.62 
Meta-analysis of trials of late steroid withdrawal in renal 
transplant recipients maintained on CSA with/without 
AZA also reported higher risk of acute rejection and graft 
failure after steroid withdrawal.63,64 With the addition of 
newer immunosuppressive drugs like MMF, TAC, SRL and 
agents for induction therapy, safety of steroid withdrawal 
has improved. MMF has been used as part of steroid sparing 
immunosuppressive regimens in combination with various 
other agents.
In two different trials, Squifﬂ  et et al and Vantenterghem 
et al used MMF/TAC and MMF/CSA respectively, to with-
draw patients from steroids at 3 months post transplantation. 
At the end of the study period, there was no signiﬁ  cant dif-
ference noted in the incidence of acute allograft rejection or 
graft/patient survival between the two groups. The steroid 
withdrawal group had lower cholesterol and triglyceride 
levels and blood pressure was better controlled.65,66
More recently investigators have tried restricting steroid 
use to the ﬁ  rst few critical days post-transplantation. Matas 
et al published data from a pilot trial withdrawing steroids at 
day 5 post transplantation in 51 living donor recipients. Anti-
thymocyte globulin was given for induction and MMF/CSA 
were given as maintenance regimen. At the end of 1 year, 
rejection-free graft survival and patient survival were similar 
between the groups.67 In 3-year follow up data on 349 trans-
plant recipients using the same rapid steroid withdrawal 
regimen, they reported 94% and 92% acute rejection free 
graft survival at the end of 1 year and 3 years respectively. 
The overall patient survival and graft survival were excellent 
compared to historic controls.68
Vincenti et al randomized patients to early steroid 
withdrawal or steroid maintenance and found no signiﬁ  cant 
differences in acute rejection episodes or patient/graft sur-
vival. Patients also received basiliximab induction and MMF/
CSA maintenance therapy.69 In another study by the same 
group, de novo kidney transplant patients were randomized to 
receive no steroids (n = 112), steroids up to day 7 (n = 115), or 
standard steroids (n = 109) with CSA microemulsion, enteric-
coated mycophenolate sodium (EC-MPS) and basiliximab. 
The 12-month incidence of BPAR, graft loss or death was 
signiﬁ  cantly lower in the standard steroid group compared to 
the two other groups. Renal function was similar in all three 
groups. The de novo use of anti-diabetic and lipid lowering 
medication was lower in one or both steroid minimization 
groups compared to standard steroids group.70
In another trial, 186 patients were randomized to steroid 
withdrawal at day 3 in conjunction with daclizumab induc-
tion and MMF/CSA maintenance compared to178 patients to 
steroid withdrawal at 4 months with MMF/CSA maintenance 
without induction therapy. At the end of 1 year, similar 
percentages of patients were steroid free with functioning 
graft in both groups and the rate of acute rejection was 15% in 
early withdrawal group vs 14% in late withdrawal group.71
In a single center, retrospective sequential analysis of 
212 renal transplant recipients with median follow up of 
5 years by Gallon et al there was no signiﬁ  cant difference 
between rate and severity of acute rejection episodes, graft 
survival, patient survival and decline of renal function 
between chronic steroid maintenance group (n = 96) and 
rapid steroid elimination group (n = 116). All patients also 
received induction with IL-2 receptor antagonist and main-
tenance immunosuppression with MMF and TAC. Patients 
in the chronic steroid group had higher incidence of hyper-
lipidemia and post transplantation diabetes compared to the 
rapid steroid elimination group.72
A meta-analysis of 6 randomized steroid withdrawal tri-
als, while receiving MMF based immunosuppression showed 
that the risk of acute rejection episodes after steroid elimi-
nation was 2.28 times higher than that observed in patients 
maintained on steroids, but this did not affect graft survival 
at medium term follow up. The reduction in total cholesterol 
level was signiﬁ  cant in the steroid withdrawal group.73
Although, the beneﬁ  ts of eliminating steroid related 
side effects are obvious, there is ongoing debate about the 
long-term safety of steroid-free maintenance immunosup-
pression protocols. Current studies on steroid free, MMF 
based immunosuppression maintenance protocols in kidney 
transplantation recipients, using T cell depleting induction 
therapy will provide more deﬁ  nite answers in near future.
Safety and tolerability
The data derived from three pivotal trials established the 
safety and tolerability of MMF in adult renal transplantation Therapeutics and Clinical Risk Management 2009:5 146
Dalal et al
recipients. MMF was generally well tolerated in most studies. 
The commonly reported adverse effects were gastrointestinal 
(GI) tract related including nausea, vomiting, diarrhea and 
abdominal pain. While the frequency of nausea was similar in 
the AZA, MMF 2 g/d and MMF 3 g/d groups, the frequency 
of vomiting, diarrhea and abdominal pain were higher with 
the MMF 2 g/d and MMF 3 g/d groups compared to the 
AZA group. Most symptoms usually resolved with dose 
reduction, interruption or withdrawal of MMF.24–26 Various 
studies in renal transplantation patients had 20% to 40% of 
patients requiring either dose reduction or withdrawal of 
MMF due to GI side effects.74–76 The impact of dose change 
and clinical outcome has been reported in several studies. In 
one study, patients with MMF dose changes during the ﬁ  rst 
year of transplantation had higher incidence of acute allograft 
rejection and signiﬁ  cant decrease in 3-year death censored 
allograft survival compared to those who did not.75 Knoll et al 
found an increase in relative risk of acute rejection by 4% 
for every week that MMF dose was reduced below the full 
dose (p = 0.02).77 In an analysis of the US Renal Data System 
(USRDS) database of cadaveric renal transplant recipients 
between 1995 to 1998, who were treated with MMF and had a 
functioning graft at 1 year post transplantation, the incidence 
of discontinuation of MMF was higher in patients with GI 
side effects, adding an additional cost of US$4500 to 8000 
to the second year after transplantation.74
All three pivotal trials reported higher incidence of inva-
sive cytomegalovirus (CMV) infections with MMF compared 
to AZA, especially in patients receiving higher dose of MMF 
3 g/d. The incidence of CMV infection was also higher with 
MMF 2 g/d than AZA at 6 months, 1 year and 3 years post 
transplantation, but was not statistically signiﬁ  cant. CMV 
infection incidence was not signiﬁ  cantly different between 
MMF 2 g/d and MMF 3 g/d groups. The increased incidence 
was possibly related to higher endoscopic surveillance as a 
part of work up for GI symptoms and the absence of standards 
of cytomegalovirus prophylaxis.24–26
At 1 and 3 years post transplantation, the incidence of 
leukopenia was signiﬁ  cantly higher in the MMF 3 g/d group 
compared to the AZA group (RR 1.13, 1.37, p  0.05 
respectively). In contrast, the incidence of leukopenia was 
lower with MMF 2/d than AZA at 6 months, 1 year and 
3 years post transplantation, but these differences were not 
statistically signiﬁ  cant. There was no signiﬁ  cant difference 
in the occurrence of anemia in all three groups at 1 year 
and 3 years post transplantation. Although the incidence of 
thrombocytopenia was lower with MMF 3 g/d compared to 
AZA at 1 year post transplantation, there was no signiﬁ  cant 
difference found between MMF 2 g/d, MMF 3 g/d and AZA 
at the end of 3 years.78
The overall skin malignancy incidence was similar for 
MMF 3 g/d and AZA groups at 3 years post transplantation. 
There was no statistical difference in skin malignancy inci-
dence between MMF 2 g/d and AZA at 1 year and 3 years 
post transplantation.78
Enteric coated mycophenolate 
sodium (EC-MPS)
Gastrointestinal complaints associated with MMF therapy 
have shown to impair physical, social and psychological 
functioning in renal transplant recipients.79 Dose reduction, 
interruption or discontinuation of MMF in patients with 
GI complaints increases the risk of acute rejection or graft 
loss.74,76,77,80 Enteric-coated mycophenolate sodium was 
developed to avoid GI side effects and to improve patient 
compliance, without compromising drug dose or efﬁ  cacy. 
EC-MPS 720 mg tablet and MMF 1000 mg tablet provides 
similar MPA maximal plasma concentration and MPA 
exposure.81
Therapeutic equivalence of MMF (1000 mg bid) and 
EC-MPS (720 mg bid) was assessed in a randomized, 
double blind study involving 423 de novo kidney transplant 
recipients. Efﬁ  cacy failure and safety proﬁ  le were assessed 
at 6 months and at 12 months. The incidences of BPAR, graft 
loss, death and loss to follow up were similar in both groups 
at 6- and 12-month periods. Among those with BPAR, the 
incidence of severe acute rejection was lower with EC-MPS 
compared to MMF (9.8% with MMF and 2.1% with EC-MPS; 
p = not signiﬁ  cant). The safety proﬁ  le and incidence of GI 
adverse events were comparable for both groups. Within 
12 months, 19.5% of MMF patients and 15% of EC-MPS 
patients required dose changes for GI adverse events. This 
study revealed that MMF 1000 mg bid and EC-MPS 720 mg 
bid are therapeutically equivalent with similar safety proﬁ  les 
in de novo renal transplant patients.82
In an open label extension of the above study, 247 patients 
received EC-MPS 720 mg bid during the 12-month 
to 36-month post-transplantation period. The type and 
severity of adverse events were comparable between the 
newly exposed and long term EC-MPS patients during 
ﬁ  rst 24-month extension. The incidence of BPAR was 5% 
(6 patients) in newly exposed group and 3% (4 patients) in 
long term EC-MPS group. The data from this study were 
compared with data of MMF-treated patients taking part in 
two other studies comparing MMF versus everolimus. In 
cross study comparisons, the incidence of efﬁ  cacy events Therapeutics and Clinical Risk Management 2009:5 147
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and safety proﬁ  le, including GI side effects, infections and 
malignancies were comparable between the two groups.83
In a pivotal, phase III, randomized, multicenter, double-
blind, double-dummy, parallel group study investigated 
safety and efﬁ  cacy of EC-MPS in stable renal transplant 
recipients. The stable renal transplant recipients on MMF 
1000 mg bid maintenance therapy with concomitant CSA 
(with/without steroids) were either continued on MMF 
(1000 mg bid) or switched to EC-MPS (720 mg bid). GI 
adverse events were comparable in both groups at 3 and 
6 months, with a trend favoring EC-MPS. Overall incidence 
of infections was similar in both groups, but there were 
fewer serious infections in the EC-MPS group (p  0.05). 
The combined incidence of BPAR, graft loss, death or loss 
to follow up was similar in both groups (EC-MPS 7.5% vs 
MMF 12.3%, p  0.05).84 At 12 months, in an open label 
extension, 130 patients initially randomized to MMF were 
converted to EC-MPS (newly exposed) and 130 patients 
initially randomized to EC-MPS were continued on 
EC-MPS (EC-MPS long term). At the end of 12-month 
extension period, incidence and type of adverse events, 
including GI side effects and malignancy were similar in 
both groups. Mean serum creatinine level was also similar 
in both groups.85
In two pooled analysis; the ﬁ  rst about the use of EC-MPS 
in de novo renal transplant patients including three multicenter 
studies (n = 456) and the second about conversion of MMF 
to EC-MPS in stable renal transplant patients also including 
three multicenter studies (n = 564), EC-MPS was well 
tolerated with comparable safety and efﬁ  cacy proﬁ  le to 
MMF.86,87
These studies revealed that EC-MPS has efﬁ  cacy and 
safety proﬁ  le similar to MMF in de novo renal transplant 
patients. Also, stable renal transplant can be safely converted 
from MMF to EC-MPS maintenance therapy and it can be 
given for long time.
In conclusion, MMF has become a mainstay of immu-
nosuppressive treatment in kidney transplantation recipi-
ents, reducing acute rejection episodes in the short term 
and improving allograft and patient survival in the long 
term. MMF in combination with new immunosuppressive 
agents can be safely utilized to offer CNI or steroid sparing 
regimens to reduce side effects. Although, MMF is usually 
well tolerated with benign side effect proﬁ  le, gastrointestinal 
adverse effects are a major concern. EC-MPS has an identical 
safety and efﬁ  cacy proﬁ  le to MMF and can be used as an 
alternative immunosuppressive agent in de novo and stable 
kidney transplantation recipients.
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